Date Announced: 28 Feb 2017
Laser system said to deliver more targeted treatment.
MOUNTAIN VIEW, Calif., Feb. 28, 2017 /PRNewswire/ -- IRIDEX Corporation (IRIX) is pleased to announce the availability of the G-Probe™ Illuminate, a new, FDA-cleared probe offering combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC). The G-Probe Illuminate marks the third member of the family of probes powered by the CYCLO G6™ Glaucoma Laser System. This latest delivery device features built-in transillumination, which optimizes placement of the probe and therapeutic outcomes.
Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia and post-corneal transplants generate even more challenges. The G-Probe Illuminate allows physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.
"The visualization of the ciliary body and the surrounding area is impressive, allowing me to tailor the treatment to meet the needs of each of my patients," says leading glaucoma specialist Steven Vold, MD. "It has really helped me to deliver a targeted CPC treatment in an easy-to-use probe."
The G-Probe Illuminate may be utilized in the operating room or as an outpatient, office-based procedure providing a versatile option for treating glaucoma. "The prevalence of glaucoma is only increasing around the world, and Iridex is committed to improving and expanding the therapeutic options for both patients and surgeons. We look forward to introducing this new glaucoma device for ophthalmologists seeking better alternatives for treating glaucoma," says IRIDEX CEO, William Moore.
Frost & Sullivan recently awarded the CYCLO G6™ Laser System with the 2016 European New Product Innovation Award. Frost & Sullivan touted this system's ability to address various stages of glaucoma as well as a range of other unique benefits, such as the repeatability and non-incisional nature of the procedures.
E-mail: via web site
Web Site: www.iridex.com